FILE 'HOME' ENTERED AT 12:03:16 ON 20 NOV 2003

=> file medicine bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'ADISCTI' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'CAPLUS' ENTERED AT 12:03:29 ON 20 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEN' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'DISSABS' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBAL' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'IFIPAT' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'IPA' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'JICST-EPLUS' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'KOSMET' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'LIFESCI' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'MEDICONF' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'MEDLINE' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'NAPRALERT' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'NLDB' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'NUTRACEUT' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'PASCAL' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'PCTGEN' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'PHARMAML' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'PHIC' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'PHIN' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'SCISEARCH' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'TOXCENTER' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'USPATFULL' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'USPAT2' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'AGRICOLA' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'ANABSTR' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'CABA' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CEABA-VTB' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CIN' ENTERED AT 12:03:29 ON 20 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGUPDATES' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'FEDRIP' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'FOMAD' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'GENBANK' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'HEALSAFE' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'NIOSHTIC' ENTERED AT 12:03:29 ON 20 NOV 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'OCEAN' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'PHAR' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'PROMT' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'RDISCLOSURE' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'SYNTHLINE' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'VETB' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'VETU' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'WPIDS' ENTERED AT 12:03:29 ON 20 NOV 2003

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s (treat? (s) relaxin and ((renal or pulmomary) (w) hypertension)
UNMATCHED LEFT PARENTHESIS '(TREAT?'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s treat? (s) relaxin and ((renal or pulmomary) (w) hypertension)

L1	0	FILE ADISCTI
L2	0	FILE ADISINSIGHT
L3	0	FILE ADISNEWS
L4	0	FILE BIOSIS
L5	0	FILE BIOTECHNO
L6	0	FILE CANCERLIT
L7	0	FILE CAPLUS
L8	0	FILE CEN
L9	0	FILE DISSABS
L10	26	FILE DGENE
L11	0	FILE DRUGB
L12	0	FILE DRUGLAUNCH
L13	0	FILE DRUGMONOG2
L14	0	FILE DRUGNL
L15	0	FILE DRUGU
L16	0	FILE EMBAL
L17	0	FILE EMBASE
L18	0	FILE ESBIOBASE
L19	1	FILE IFIPAT
L20	0	FILE IPA
L21	0	FILE JICST-EPLUS
L22	0	FILE KOSMET
L23	0	FILE LIFESCI
L24	0	FILE MEDICONF
L25	0	FILE MEDLINE
L26	0	FILE NAPRALERT
L27	0	FILE NLDB
L28	0	FILE NUTRACEUT

```
L29             0 FILE PASCAL
L30             0 FILE PCTGEN
L31             0 FILE PHARMAML
L32             0 FILE PHIC
L33             0 FILE PHIN
L34             0 FILE SCISEARCH
L35             0 FILE TOXCENTER
L36             1 FILE USPATFULL
L37             0 FILE USPAT2
L38             0 FILE AGRICOLA
L39             0 FILE ANABSTR
L40             0 FILE AQUASCI
L41             0 FILE BIOBUSINESS
L42             0 FILE BIOCOMMERCE
L43             0 FILE BIOTECHDS
L44             0 FILE CABA
L45             0 FILE CEABA-VTB
L46             0 FILE CIN
L47             0 FILE CONFSCI
L48             0 FILE CROPB
L49             0 FILE CROPU
L50             0 FILE DRUGUPDATES
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'TREAT? (S) RELAXIN'
L51             0 FILE FEDRIP
L52             0 FILE FOMAD
L53             0 FILE FOREGE
L54             0 FILE FROSTI
L55             0 FILE FSTA
L56             0 FILE GENBANK
L57             0 FILE HEALSAFE
L58             0 FILE NIOSHTIC
L59             0 FILE NTIS
L60             0 FILE OCEAN
L61             0 FILE PHAR
L62             0 FILE PROMT
L63             0 FILE RDISCLOSURE
L64             0 FILE SYNTHLINE
L65             0 FILE VETB
L66             0 FILE VETU
L67             1 FILE WPIDS

TOTAL FOR ALL FILES
L68            29 TREAT? (S) RELAXIN AND ((RENAL OR PULMOMARY) (W) HYPERTENSION)

=> rem dup l68
DUP IS NOT VALID HERE
The DELETE command is used to remove various items stored by the
system.

To delete a saved query, saved answer set, saved L-number list, SDI
request, batch request, mailing list, or user-defined cluster, format,
or search field, enter the name.  The name may include ?  for left,
right, or simultaneous left and right truncation.

Examples:

  DELETE BIO?/Q          - delete query names starting with BIO
  DELETE ?DRUG/A         - delete answer set names ending with DRUG
  DELETE ?ELEC?/L        - delete L-number lists containing ELEC
  DELETE ANTICOAG/S      - delete SDI request
  DELETE ENZYME/B        - delete batch request
  DELETE .MYCLUSTER      - delete user-defined cluster
  DELETE .MYFORMAT       - delete user-defined display format
  DELETE .MYFIELD        - delete user-defined search field
```

```
  DELETE NAMELIST MYLIST - delete mailing list

To delete an ordered document or an offline print, enter its
number.

Examples:

  DELETE P123001C         - delete print request
  DELETE D134002C         - delete document order request

To delete an individual L-number or range of L-numbers, enter the
L-number or L-number range.  You may also enter DELETE LAST followed
by a number, n, to delete the last n L-numbers.  RENUMBER or
NORENUMBER may also be explicitly specified to override the value of
SET RENUMBER.

Examples:

  DELETE L21              - delete a single L-number
  DELETE L3-L6            - delete a range of L-numbers
  DELETE LAST 4           - delete the last 4 L-numbers
  DELETE L33-             - delete L33 and any higher L-number
  DELETE -L55             - delete L55 and any lower L-number
  DELETE L2-L6 RENUMBER - delete a range of L-numbers and
                          renumber remaining L-numbers
  DELETE RENUMBER         - renumber L-numbers after deletion of
                          intermediate L-numbers

Entire sets of saved items, SDI requests, batch requests, user-defined
items, or E-numbers can be deleted.

Examples:

  DELETE SAVED/Q - delete all saved queries
  DELETE SAVED/A - delete all saved answer sets
  DELETE SAVED/L - delete all saved L-number lists
  DELETE SAVED   - delete all saved queries, answer sets,
                   and L-number lists
  DELETE SAVED/S - delete all SDI requests
  DELETE SAVED/B - delete all batch requests
  DELETE CLUSTER - delete all user-defined clusters
  DELETE FORMAT  - delete all user-defined display formats
  DELETE FIELD   - delete all user-defined search fields
  DELETE SELECT  - delete all E-numbers
  DELETE HISTORY - delete all L-numbers and restart the
                   session at L1

To delete an entire multifile SDI request, enter DELETE and
the name of the request.  To delete a component from the
multifile SDI, enter DELETE and the name of the component.

=> dup rem l68
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGLAUNCH,
DRUGMONOG2, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHARMAML, BIOCOMMERCE,
DRUGUPDATES, FEDRIP, FOREGE, GENBANK, PHAR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L68
L69          28 DUP REM L68 (1 DUPLICATE REMOVED)

=> d l69 1-28 ibib abs

L69  ANSWER 1 OF 28  IFIPAT  COPYRIGHT 2003 IFI on STN DUPLICATE 1
AN                        10075796  IFIPAT;IFIUDB;IFICDB
TITLE:                    USE OF RELAXIN TREAT DISEASES
                          RELATED TO VASOCONSTRICTION; HYPOTENSIVE,
```

ANTIISCHEMIC AND WOUND HEALING AGENTS

INVENTOR(S): Conrad; Kirk P., Cranberry Township, PA, US
Huang; Xinfan, Menlo Park, CA, US
Lewis; Martyn, Menlo park, CA, US
Tozzi; Carol A., Jackson, NJ, US
Unemori; Elaine N., Oakland, CA, US
PATENT ASSIGNEE(S): Unassigned
AGENT: Paula A. Borden BOZICEVIC, FIELD & FRANCIS LLP, 200 Middlefield Road, Suite 200, Menlo Park, CA, 94025, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2002019349	A1	20020214
APPLICATION INFORMATION:	US 2001-780752		20010209

	NUMBER	DATE
PRIORITY APPLN. INFO.:	US 2000-181408P	20000209 (Provisional)
	US 2000-200284P	20000428 (Provisional)
	US 2000-242216P	20001020 (Provisional)
FAMILY INFORMATION:	US 2002019349	20020214

DOCUMENT TYPE: Utility
Patent Application - First Publication
FILE SEGMENT: CHEMICAL
APPLICATION

GOVERNMENT INTEREST:

(0002) The United States Government may have certain rights in this application pursuant to National Institutes of Health grants RO1 HD30325 and KO04 HD01098.

NUMBER OF CLAIMS: 27 15 Figure(s).

DESCRIPTION OF FIGURES:

FIGS. 1A-D depict the effect of long-term infusion of purified porcine RLX, recombinant human **relaxin** (rhRLX), or vehicle on mean arterial pressure (A), glomerular filtration rate (B), effective renal plasma flow (C), and effective renal vascular resistance (D). The numbers in parentheses depict the number of rats tested. *p less-than 0.05 vs baseline and vehicle.

FIGS. 2A-D depict the effect of 5-day administration of rhRLX to sham ovariectomized and ovariectomized rats: (A) mean arterial pressure, (B) glomerular filtration rate, (C) effective renal plasma flow, and (D) effective renal vascular resistance. The numbers in parentheses depict the number of rats investigated. *p less-than 0.05 vs baseline.

FIGS. 3A-D are graphs depicting the effect of a 5-day infusion of either rhRLX (4 mu g/hour) or vehicle (time-control) on MAP (panel A), GFR (B), ERPF (C) or ERVR (D) in conscious male rats. *p less-than 0.05 vs baseline.

FIGS. 4A-D are graphs depicting the effect of the specific ETB receptor antagonist, RES-701-1, on MAP (panel A), GFR (B), ERPF (C), and ERVR (D) in rats administered either rhRLX (4 mu g/h) or vehicle for 5 days. +p less-than 0.05 **relaxin** baseline vs vehicle baseline. *p less-than 0.05 RES-701-1 vs baseline.

FIG. 5 is a graph depicting real-time quantitative RT-PCR analysis of expression of the rat VEGF164 and VEGF120 isoforms and rat bFGF in the peri-infarct area of rat hearts postmyocardial infarction.

FIG. 6 is a graph depicting real-time quantitative RT-PCR of the human VEGF165 and VEGF121 isoforms and human bFGF following **relaxin** ***treatment*** in vitro.

FIG. 7 is a graph depicting the effect of chronic administration of ***relaxin*** on right ventricular pressure (RVP) in rats kept under conditions of normoxia (air) or hypoxia.

FIGS. 8A and 8B are graphs depicting the effects of **relaxin** on VEGF and bFGF mRNA expression in wound cells. FIG. 8A depicts expression of transcripts of the 164-amino acid and 120-amino acid isoforms of VEGF. FIG. 8B depicts the increase in expression of bFGF in wound cells.

FIG. 9 is a graph depicting the effect of **relaxin** on VEGF (165and 121-amino acid isoforms) and bFGF mRNA expression in THP-1 cells.

FIG. 10 is a graph depicting the change in diastolic blood pressure from baseline over a period of 26 weeks in humans **treated** with 25 mu g/kg/day **relaxin** (solid triangles) or placebo (open squares) humans for 24 weeks.
FIG. 11 is a graph depicting the change in systolic blood pressure from baseline over a period of 26 weeks in humans **tr ated** with 25 mu g/kg/day **relaxin** (solid triangles) or placebo (open squares) humans for 24 weeks.
FIG. 12 is a graph depicting predicted creatinine clearance versus time in humans **treated** with 10 mu g/kg/day **relaxin**.
FIG. 13 is a graph depicting predicted creatinine clearance versus time in humans **treated** with 25 mu g/kg/day **relaxin**.
FIG. 14 is a graph depicting myogenic reactivity of small renal arteres.
FIG. 15 is a graph depicting myogenic reactivity of small mesenteric arteries.

AB The invention relates to methods of **treating** diseases related to vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active **relaxin**. **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females, and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction.

CLMN 27 15 Figure(s).

FIGS. 1A-D depict the effect of long-term infusion of purified porcine RLX, recombinant human **relaxin** (rhRLX), or vehicle on mean arterial pressure (A), glomerular filtration rate (B), effective renal plasma flow (C), and effective renal vascular resistance (D). The numbers in parentheses depict the number of rats tested. *p less-than 0.05 vs baseline and vehicle.

FIGS. 2A-D depict the effect of 5-day administration of rhRLX to sham ovariectomized and ovariectomized rats: (A) mean arterial pressure, (B) glomerular filtration rate, (C) effective renal plasma flow, and (D) effective renal vascular resistance. The numbers in parentheses depict the number of rats investigated. *p less-than 0.05 vs baseline.

FIGS. 3A-D are graphs depicting the effect of a 5-day infusion of either rhRLX (4 mu g/hour) or vehicle (time-control) on MAP (panel A), GFR (B), ERPF (C) or ERVR (D) in conscious male rats. *p less-than 0.05 vs baseline.

FIGS. 4A-D are graphs depicting the effect of the specific ETB receptor antagonist, RES-701-1, on MAP (panel A), GFR (B), ERPF (C), and ERVR (D) in rats administered either rhRLX (4 mu g/h) or vehicle for 5 days. +p less-than 0.05 **relaxin** baseline vs vehicle baseline. *p less-than 0.05 RES-701-1 vs baseline.

FIG. 5 is a graph depicting real-time quantitative RT-PCR analysis of expression of the rat VEGF164 and VEGF120 isoforms and rat bFGF in the peri-infarct area of rat hearts postmyocardial infarction.

FIG. 6 is a graph depicting real-time quantitative RT-PCR of the human VEGF165 and VEGF121 isoforms and human bFGF following **relaxin treatment** in vitro.

FIG. 7 is a graph depicting the effect of chronic administration of **relaxin** on right ventricular pressure (RVP) in rats kept under conditions of normoxia (air) or hypoxia.

FIGS. 8A and 8B are graphs depicting the effects of **relaxin** on VEGF and bFGF mRNA expression in wound cells. FIG. 8A depicts expression of transcripts of the 164-amino acid and 120-amino acid isoforms of VEGF. FIG. 8B depicts the increase in expression of bFGF in wound cells.

FIG. 9 is a graph depicting the effect of **relaxin** on VEGF (165and 121-amino acid isoforms) and bFGF mRNA expression in THP-1 cells.

FIG. 10 is a graph depicting the change in diastolic blood pressure from baseline over a period of 26 weeks in humans **treated** with 25 mu g/kg/day **relaxin** (solid triangles) or placebo (open squares) humans for 24 weeks.

FIG. 11 is a graph depicting the change in systolic blood pressure from baseline over a period of 26 weeks in humans **treat d** with 25 mu g/kg/day **relaxin** (solid triangles) or placebo (open squares) humans for 24 weeks.

FIG. 12 is a graph depicting predicted creatinine clearance versus time in

humans **treated** with 10 mu g/kg/day **relaxin**.
FIG. 13 is a graph depicting predicted creatinine clearance versus time in humans **treat d** with 25 mu g/kg/day **relaxin**.
FIG. 14 is a graph depicting myogenic reactivity of small renal arteres.
FIG. 15 is a graph depicting myogenic reactivity of small mesenteric arteries.

L69 ANSWER 2 OF 28 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: 2001-514619 [56] WPIDS
DOC. NO. CPI: C2001-153811
TITLE: **Treating** pulmonary or **renal hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin**.
DERWENT CLASS: B04 D16
INVENTOR(S): CONRAD, K P; HUANG, X; LEWIS, M; TOZZI, C A; UNEMORI, E N
PATENT ASSIGNEE(S): (CONN-N) CONNETICS CORP; (UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY; (UYPI-N) UNIV PITTSBURGH; (CONR-I) CONRAD K P; (HUAN-I) HUANG X; (LEWI-I) LEWIS M; (TOZZ-I) TOZZI C A; (UNEM-I) UNEMORI E N
COUNTRY COUNT: 95
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001058468	A1	20010816	(200156)*	EN	73
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
AU 2001036886	A	20010820	(200175)		
US 2002019349	A1	20020214	(200214)		
EP 1253929	A1	20021106	(200281)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 2001058468	A1		WO 2001-US4370	20010209
AU 2001036886	A		AU 2001-36886	20010209
US 2002019349	A1	Provisional	US 2000-181408P	20000209
		Provisional	US 2000-200284P	20000428
		Provisional	US 2000-242216P	20001020
			US 2001-780752	20010209
EP 1253929	A1		EP 2001-909098	20010209
			WO 2001-US4370	20010209

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2001036886	A	Based on	WO 2001058468
EP 1253929	A1	Based on	WO 2001058468

PRIORITY APPLN. INFO: US 2000-242216P 20001020; US 2000-181408P 20000209; US 2000-200284P 20000428; US 2001-780752 20010209
AN 2001-514619 [56] WPIDS
AB WO 200158468 A UPAB: 20011001
NOVELTY - **Treating** hypertension, increasing vasodilation,

increasing renal function, **tr ating** ischemic condition, promoting wound healing, increasing production of an angiogenic cytokine, increasing nitric oxide production, and increasing endothelin type B receptor activation, in an individual, comprises administering **relaxin**.

DETAILED DESCRIPTION - **Treating** hypertension, increasing vasodilation, increasing renal function by increasing a parameter associated with renal function, **treating** ischemic condition, promoting wound healing, increasing production of an angiogenic cytokine, increasing nitric oxide production in endothelial cell of a blood vessel endothelium, and for increasing endothelin type B receptor activation in an endothelial cell in blood vessel endothelium, in an individual, comprises administering a formulation containing **relaxin**.

ACTIVITY - Hypotensive; vasotropic; cerebroprotective; vulnerary. To test the effect of **relaxin** in improving kidney function in humans, a clinical trait was conducted with human subjects, age 18-70 years. Subjects were **treated** with either 10 micro g **relaxin**/kg body weight/day, 25 micro g **relaxin**/kg body weight/day or placebo for 24 weeks. Administration was by continuous subcutaneous infusion using a pump. The **relaxin** was recombinant human **relaxin** (rhRLXN). At various time points, diastolic blood pressure, systolic blood pressure and creatinine (as a measure of renal function) were measured. Creatinine clearance was calculated. The results indicated that **treatment** with 25 micro g/kg/day dose of recombinant human rhRLXN reduced diastolic and systolic blood pressure significantly from about week 2 through week 24. The threshold for obtaining this effect was greater than 10 micro g rhRLXN/kg/day. The results further indicated that at both the 10 and 25 micro g rhRLXN/kg/day **treatments** resulted in an improvement in renal function, as measured by an increase in creatinine clearance. This latter result indicated an increase in blood flow. Taken together, the data demonstrated that **treatment** with greater than 10 micro g rhRLXN/kg body weight/day was effective in increasing cardiac output. The reduction in the cardiac afterload without a worsening in renal function indicated that there was a concomitant increase in cardiac output as a result of the **treatment**.

MECHANISM OF ACTION - Glomerular filtration enhancer; vasodilation enhancer; neovascularization enhancer; angiogenesis enhancer; wound healing promoter; gene therapy.

USE - The method is used for **treating** renal or pulmonary hypertension, **treating** ischemic conditions such as ischemic wound, stroke or ischemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium, and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium (claimed). **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction, and for increasing angiogenesis, promotes neovascularization in both males and females. It also promotes renal vasodilation and hyperfiltration.

ADVANTAGE - **Relaxin** has high safety profile in humans which is superior to other agents such as vascular endothelial growth factor and fibroblast growth factor. It is also effective in **treating** hypertensive vascular diseases both in males and females.

Dwg.0/15

L69 ANSWER 3 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14414 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises

administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Human GAPDH-alpha-sense RT-PCR primer.
AN AAD14414 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify human GAPDH.

L69 ANSWER 4 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14413 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Human GAPDH-sense RT-PCR primer.
AN AAD14413 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary

hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human GAPDH.

L69 ANSWER 5 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14412 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Human GAPDH sense probe.
AN AAD14412 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of human GAPDH.

L69 ANSWER 6 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14411 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing

vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Human HGF-alpha-sense RT-PCR primer.
AN AAD14411 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify human HGF.

L69 ANSWER 7 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14410 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Human HGF-sense RT-PCR primer.
AN AAD14410 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in

treating a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human HGF.

L69 ANSWER 8 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14409 DNA DGENE
TITLE: **Treating** pulmonary or **renal hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Human basic fibroblast growth factor (bFGF)-alpha-sense RT-PCR primer.
AN AAD14409 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify human bFGF.

L69 ANSWER 9 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN

ACCESSION NUMBER: AAD14408 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Human basic fibroblast growth factor (bFGF)-sense RT-PCR primer.
AN AAD14408 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human bFGF.

L69 ANSWER 10 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14407 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Human basic fibroblast growth factor (bFGF) sense probe.
AN AAD14407 DNA DGENE

AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of human bFGF.

L69 ANSWER 11 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14406 DNA DGENE
TITLE: **Treating** pulmonary or **renal hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Human VEGF121-alpha-sense RT-PCR primer.
AN AAD14406 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **R laxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify

human vascular endothelial cell growth factor (VEGF) 121.

L69 ANSWER 12 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14405 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Human VEGF121-sense RT-PCR primer.
AN AAD14405 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human vascular endothelial cell growth factor (VEGF) 121.

L69 ANSWER 13 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14404 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]

DESCRIPTION: Human vascular endothelial cell growth factor (VEGF) 121 sense probe.

AN AAD14404 DNA DGENE

AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **R laxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of human rat vascular endothelial cell growth factor (VEGF) 121.

L69 ANSWER 14 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN

ACCESSION NUMBER: AAD14403 DNA DGENE

TITLE: **Treating** pulmonary or **renal hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

DESCRIPTION: Human VEGF165-alpha-sense RT-PCR primer.

AN AAD14403 DNA DGENE

AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females.

It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify human vascular endothelial cell growth factor (VEGF) 165.

L69 ANSWER 15 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14402 DNA DGENE
TITLE: **Treating** pulmonary or **renal hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Human VEGF165-sense RT-PCR primer.
AN AAD14402 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **R laxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human vascular endothelial cell growth factor (VEGF) 165.

L69 ANSWER 16 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14401 DNA DGENE
TITLE: **Treating** pulmonary or **renal hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Human vascular endothelial cell growth factor (VEGF) 165 sense probe.

AN AAD14401 DNA DGENE

AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of human rat vascular endothelial cell growth factor (VEGF) 165.

L69 ANSWER 17 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14400 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Rat GAPDH-alpha-sense RT-PCR primer.

AN AAD14400 DNA DGENE

AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating**

diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify rat GAPDH.

L69 ANSWER 18 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14399 DNA DGENE
TITLE: **Treating** pulmonary or **renal hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Rat GAPDH-sense RT-PCR primer.
AN AAD14399 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify rat GAPDH.

L69 ANSWER 19 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14398 DNA DGENE
TITLE: **Treating** pulmonary or **renal hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Rat GAPDH sense probe.
AN AAD14398 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of rat GAPDH.

L69 ANSWER 20 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14397 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Rat basic fibroblast growth factor (bFGF)-alpha-sense RT-PCR primer.
AN AAD14397 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an

endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify rat bFGF.

L69 ANSWER 21 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14396 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Rat basic fibroblast growth factor (bFGF)-sense RT-PCR primer.
AN AAD14396 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify rat bFGF.

L69 ANSWER 22 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14395 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Rat basic fibroblast growth factor (bFGF) sense probe.
AN AAD14395 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of rat bFGF.

L69 ANSWER 23 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14394 DNA DGENE
TITLE: **Treating** pulmonary or **renal hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Rat VEGF120-alpha-sense RT-PCR primer.
AN AAD14394 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF)

or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify rat vascular endothelial cell growth factor (VEGF) 120.

L69 ANSWER 24 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14393 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Rat VEGF120-sense RT-PCR primer.
AN AAD14393 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify rat vascular endothelial cell growth factor (VEGF) 120.

L69 ANSWER 25 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14392 DNA DGENE
TITLE: **Tr ating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Rat vascular endothelial cell growth factor (VEGF) 120 sense probe.
AN AAD14392 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of rat vascular endothelial cell growth factor (VEGF) 120.

L69 ANSWER 26 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14391 DNA DGENE
TITLE: **Treating** pulmonary or **renal** **hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Rat VEGF164-alpha-sense RT-PCR primer.
AN AAD14391 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary

hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify rat vascular endothelial cell growth factor (VEGF) 164.

L69 ANSWER 27 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14390 DNA DGENE
TITLE: **Treating** pulmonary or **renal hypertension** and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
DESCRIPTION: Rat VEGF164-sense RT-PCR primer.
AN AAD14390 DNA DGENE
AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify rat vascular endothelial cell growth factor (VEGF) 164.

L69 ANSWER 28 OF 28 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAD14389 DNA DGENE
TITLE: **Treating** pulmonary or **renal hypertension** and an ischemic condition, increasing

vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N)CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

DESCRIPTION: Rat vascular endothelial cell growth factor (VEGF) 164 sense probe.

AN AAD14389 DNA DGENE

AB The invention relates to methods of **treating** diseases related to vasodilation by administering pharmaceutically active **relaxin** . **Relaxin** functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in **treating** a wide variety of diseases relating to vasoconstriction. The method is used for **treating** renal or pulmonary hypertension, **treating** ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for **treating** diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of rat vascular endothelial cell growth factor (VEGF) 164.

=>

WEST Search History

DATE: Thursday, November 20, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L3	L2 and administ$	15	L3
L2	treat$ same relaxin and ((renal or pulmomary) same hypertension)	15	L2
L1	treat$ same hypertension same relaxin	6	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 6 of 6 returned.

1. Document ID: US 20020019349 A1

L1: Entry 1 of 6 File: PGPB Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019349
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020019349 A1

TITLE: Use of relaxin treat diseases related to vasoconstriction

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Conrad, Kirk P.	Cranberry Township	PA	US	
Lewis, Martyn	Menlo park	CA	US	
Unemori, Elaine N.	Oakland	CA	US	
Huang, Xinfan	Menlo Park	CA	US	
Tozzi, Carol A.	Jackson	NJ	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

2. Document ID: US 5952296 A

L1: Entry 2 of 6 File: USPT Sep 14, 1999

US-PAT-NO: 5952296
DOCUMENT-IDENTIFIER: US 5952296 A

TITLE: Method of using relaxin as therapeutic or preventing agent

DATE-ISSUED: September 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bigazzi; Mario	Florence			IT

US-CL-CURRENT: 514/3; 514/12, 514/822, 514/885

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

3. Document ID: US 5364841 A

L1: Entry 3 of 6 File: USPT Nov 15, 1994

US-PAT-NO: 5364841
DOCUMENT-IDENTIFIER: US 5364841 A
**** See image for Certificate of Correction ****

TITLE: Treatment of obesity and essential hypertension and related disorders

DATE-ISSUED: November 15, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Solana Beach	CA		
Leighton; Brendan	Eynsham			GB2

US-CL-CURRENT: 514/12; 514/13, 514/14, 514/15, 514/16, 514/17, 514/4

4. Document ID: US 5280014 A

L1: Entry 4 of 6 File: USPT Jan 18, 1994

US-PAT-NO: 5280014
DOCUMENT-IDENTIFIER: US 5280014 A

TITLE: Treatment of obesity and essential hypertension and related disorders

DATE-ISSUED: January 18, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Solana Beach	CA		
Leighton; Brendan	Eynsham			GB2

US-CL-CURRENT: 514/12; 514/13, 514/14, 514/15, 514/16, 514/17, 514/4



5. Document ID: WO 2003030930 A1

L1: Entry 5 of 6 File: DWPI Apr 17, 2003

DERWENT-ACC-NO: 2003-393413
DERWENT-WEEK: 200337
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Treating e.g. peuripheral vascular disease, psychiatric, immunological, depressive, addictive, neurologic or degenerative disorders, comprises administering human 3 relaxin or its analogue

INVENTOR: BATHGATE, R A D; BURAZIN, T C ; GUNDLACH, A L ; SAMUEL, C S ; TREGEAR, G ; WADE, J D

PRIORITY-DATA: 2001AU-0008144 (October 8, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 2003030930 A1	April 17, 2003	E	037	A61K038/22

INT-CL (IPC): A61 K 38/22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

6. Document ID: EP 1253929 A1 WO 200158468 A1 AU 200136886 A US 20020019349 A1

L1: Entry 6 of 6 File: DWPI Nov 6, 2002

DERWENT-ACC-NO: 2001-514619
DERWENT-WEEK: 200281

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin

INVENTOR: CONRAD, K P; HUANG, X ; LEWIS, M ; TOZZI, C A ; UNEMORI, E N

PRIORITY-DATA: 2000US-242216P (October 20, 2000), 2000US-181408P (February 9, 2000), 2000US-200284P (April 28, 2000), 2001US-0780752 (February 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1253929 A1	November 6, 2002	E	000	A61K038/00
WO 200158468 A1	August 16, 2001	E	073	A61K038/00
AU 200136886 A	August 20, 2001		000	A61K038/00
US 20020019349 A1	February 14, 2002		000	A61K038/00

INT-CL (IPC): A61 K 38/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection | Print

Term	Documents
HYPERTENSION	38805
HYPERTENSIONS	122
RELAXIN	956
RELAXINS	57
TREAT$	0
TREAT	516752
TREATA	1
TREATABIL	1
TREATABILIT	1
TREATABILITIES	2
(TREAT$ SAME HYPERTENSION SAME RELAXIN).USPT,PGPB,EPAB,DWPI,TDBD.	6

There are more results than shown above. Click here to view the entire set.

Display Format: Change Format

Previous Page Next Page

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 15 of 15 returned.

1. Document ID: US 20030187246 A1

L2: Entry 1 of 15 File: PGPB Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030187246
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030187246 A1

TITLE: Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Doberstein, Stephen Kohl	San Francisco	CA	US	
Buchman, Andrew Roy	Berkeley	CA	US	
Ferguson, Kimberly Carr	Pacifica	CA	US	
Homburger, Sheila Akiko	Oakland	CA	US	
Platt, Darren Mark	San Francisco	CA	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/455, 435/6, 435/69.1, 530/303, 530/388.25, 800/8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Draw Desc | Image

2. Document ID: US 20030149997 A1

L2: Entry 2 of 15 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030149997
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030149997 A1

TITLE: Diagnostics and therapeutics for arterial wall disruptive disorders

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hageman, Gregory S.	Coralville	IA	US	

US-CL-CURRENT: 800/8; 435/6, 435/7.1, 800/9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Draw Desc | Image

3. Document ID: US 20030148955 A1

L2: Entry 3 of 15 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148955
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148955 A1

TITLE: Soluble tumor necrosis factor receptor treatment of medical disorders

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pluenneke, John D.	Parkville	MO	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

4. Document ID: US 20030113319 A1

L2: Entry 4 of 15 File: PGPB Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030113319
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030113319 A1

TITLE: Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Leibovitz, Shamir	Tel Aviv		IL	

US-CL-CURRENT: 424/141.1; 424/145.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

5. Document ID: US 20030099651 A1

L2: Entry 5 of 15 File: PGPB May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030099651
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030099651 A1

TITLE: Method and pharmaceutical composition for inhibiting premature rupture of fetal membranes, ripening of uterine cervix and preterm labor in mammals

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Leibovitz, Shamir	Tel Aviv		IL	

US-CL-CURRENT: 424/145.1; 424/718, 514/165, 514/469

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

6. Document ID: US 20030087411 A1

L2: Entry 6 of 15 File: PGPB May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087411
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087411 A1

TITLE: Death associated kinase containing ankyr in repeats (DAKAR) and methods of use

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Holland, Pamela M.	Seattle	WA	US	
Peschon, Jacques J.	Seattle	WA	US	
Virca, George D.	Bellevue	WA	US	

US-CL-CURRENT: 435/194; 435/320.1, 435/325, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

7. Document ID: US 20020031513 A1

L2: Entry 7 of 15 File: PGPB Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020031513
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020031513 A1

TITLE: Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Leibovitz, Shamir	Tel Aviv		IL	

US-CL-CURRENT: 424/141.1; 514/509, 514/562, 514/565, 514/575

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

8. Document ID: US 20020019349 A1

L2: Entry 8 of 15 File: PGPB Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019349
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020019349 A1

TITLE: Use of relaxin treat diseases related to vasoconstriction

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Conrad, Kirk P.	Cranberry Township	PA	US	
Lewis, Martyn	Menlo park	CA	US	
Unemori, Elaine N.	Oakland	CA	US	
Huang, Xinfan	Menlo Park	CA	US	
Tozzi, Carol A.	Jackson	NJ	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Draw Desc | Image

9. Document ID: US 20010021380 A1

L2: Entry 9 of 15 File: PGPB Sep 13, 2001

PGPUB-DOCUMENT-NUMBER: 20010021380
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010021380 A1

TITLE: Soluble tumor necrosis factor receptor treatment of medical disorders

PUBLICATION-DATE: September 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pluenneke, John D.	Kansas City	MO	US	

US-CL-CURRENT: 424/131.1; 514/171, 514/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Draw Desc | Image

10. Document ID: US 6627746 B1

L2: Entry 10 of 15 File: USPT Sep 30, 2003

US-PAT-NO: 6627746
DOCUMENT-IDENTIFIER: US 6627746 B1

TITLE: Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof

DATE-ISSUED: September 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Doberstein; Stephen Kohl	San Francisco	CA		
Platt; Darren Mark	San Francisco	CA		
Ferguson; Kimberly Carr	Pacifica	CA		
Buchman; Andrew Roy	Berkeley	CA		
Homburger; Sheila Akiko	Oakland	CA		

US-CL-CURRENT: 536/23.5; 435/69.1, 530/303, 530/350, 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Draw Desc | Image

11. Document ID: US 6468770 B1

L2: Entry 11 of 15 File: USPT Oct 22, 2002

US-PAT-NO: 6468770
DOCUMENT-IDENTIFIER: US 6468770 B1

TITLE: Nucleic acids and proteins of D. melanogaster insulin-like genes and uses thereof

DATE-ISSUED: October 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Keyes; Linda Nolan	San Carlos	CA		
Doberstein; Stephen Kohl	San Francisco	CA		
Buchman; Andrew Roy	Berkeley	CA		
Reddy; Bindu Priya	San Francisco	CA		
Ruddy; David Andrew	San Francisco	CA		

US-CL-CURRENT: 435/69.4; 435/320.1, 435/325, 435/455, 435/471, 435/69.1, 536/23.1, 536/23.5, 536/23.51

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Draw Desc | Image

12. Document ID: US 6135942 A

L2: Entry 12 of 15 File: USPT Oct 24, 2000

US-PAT-NO: 6135942
DOCUMENT-IDENTIFIER: US 6135942 A

TITLE: Nucleic acids proteins of a D. melanogaster insulin-like gene and uses thereof

DATE-ISSUED: October 24, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Leptin; Maria	Cologne			DE

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/348, 435/69.1, 435/69.4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Draw Desc | Image

13. Document ID: US 5364841 A

L2: Entry 13 of 15 File: USPT Nov 15, 1994

US-PAT-NO: 5364841

DOCUMENT-IDENTIFIER: US 5364841 A
**** See imag for Certificate of Correction ****

TITLE: Treatment of obesity and essential hypertension and related disorders

DATE-ISSUED: November 15, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Solana Beach	CA		
Leighton; Brendan	Eynsham			GB2

US-CL-CURRENT: 514/12; 514/13, 514/14, 514/15, 514/16, 514/17, 514/4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinIC | Draw Desc | Image

14. Document ID: US 5280014 A

L2: Entry 14 of 15 File: USPT Jan 18, 1994

US-PAT-NO: 5280014
DOCUMENT-IDENTIFIER: US 5280014 A

TITLE: Treatment of obesity and essential hypertension and related disorders

DATE-ISSUED: January 18, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Solana Beach	CA		
Leighton; Brendan	Eynsham			GB2

US-CL-CURRENT: 514/12; 514/13, 514/14, 514/15, 514/16, 514/17, 514/4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinIC | Draw Desc | Image

15. Document ID: EP 1253929 A1 WO 200158468 A1 AU 200136886 A US 20020019349 A1

L2: Entry 15 of 15 File: DWPI Nov 6, 2002

DERWENT-ACC-NO: 2001-514619
DERWENT-WEEK: 200281
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin

INVENTOR: CONRAD, K P; HUANG, X ; LEWIS, M ; TOZZI, C A ; UNEMORI, E N

PRIORITY-DATA: 2000US-242216P (October 20, 2000), 2000US-181408P (February 9, 2000), 2000US-200284P (April 28, 2000), 2001US-0780752 (February 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1253929 A1	November 6, 2002	E	000	A61K038/00
WO 200158468 A1	August 16, 2001	E	073	A61K038/00
AU 200136886 A	August 20, 2001		000	A61K038/00
US 20020019349 A1	February 14, 2002		000	A61K038/00

INT-CL (IPC): A61 K 38/00

Generate Collection | Print

Term	Documents
RELAXIN	956
RELAXINS	57
RENAL	39351
RENALS	89
PULMOMARY	2
PULMOMARIES	0
PULMOMARYS	0
HYPERTENSION	38805
HYPERTENSIONS	122
TREAT$	0
(TREAT$ SAME RELAXIN AND ((RENAL OR PULMOMARY) SAME HYPERTENSION)).USPT,PGPB,EPAB,DWPI,TDBD.	15

There are more results than shown above. Click here to view the entire set.

Display Format: | Change Format